Syndax Pharmaceuticals, Inc. (SNDX) Position Held by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. continued to hold its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the second quarter, according to its most recent filing with the SEC. The firm owned 10,100 shares of the company’s stock at the end of the second quarter. Schwab Charles Investment Management Inc.’s holdings in Syndax Pharmaceuticals were worth $142,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Bank of Montreal Can acquired a new stake in Syndax Pharmaceuticals in the 2nd quarter valued at about $158,000. TIAA CREF Investment Management LLC raised its position in Syndax Pharmaceuticals by 36.2% in the 1st quarter. TIAA CREF Investment Management LLC now owns 22,924 shares of the company’s stock valued at $315,000 after purchasing an additional 6,091 shares in the last quarter. Bank of New York Mellon Corp raised its position in Syndax Pharmaceuticals by 43.5% in the 1st quarter. Bank of New York Mellon Corp now owns 29,227 shares of the company’s stock valued at $401,000 after purchasing an additional 8,861 shares in the last quarter. Geode Capital Management LLC raised its position in Syndax Pharmaceuticals by 10.5% in the 1st quarter. Geode Capital Management LLC now owns 98,962 shares of the company’s stock valued at $1,357,000 after purchasing an additional 9,410 shares in the last quarter. Finally, Morgan Stanley raised its position in Syndax Pharmaceuticals by 209.0% in the 1st quarter. Morgan Stanley now owns 119,987 shares of the company’s stock valued at $1,646,000 after purchasing an additional 81,159 shares in the last quarter. 64.31% of the stock is currently owned by institutional investors.

A number of equities research analysts have issued reports on the company. Oppenheimer Holdings, Inc. increased their price target on Syndax Pharmaceuticals to $29.00 and gave the company an “outperform” rating in a research report on Friday, August 11th. Zacks Investment Research lowered Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Citigroup Inc. set a $20.00 price target on Syndax Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 11th. Nomura reduced their price target on Syndax Pharmaceuticals from $27.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, August 11th. Finally, Instinet reaffirmed a “buy” rating and issued a $22.00 price target (down previously from $27.00) on shares of Syndax Pharmaceuticals in a research report on Monday, August 14th. Two analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Syndax Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $23.13.

ILLEGAL ACTIVITY NOTICE: “Syndax Pharmaceuticals, Inc. (SNDX) Position Held by Schwab Charles Investment Management Inc.” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://sportsperspectives.com/2017/11/15/syndax-pharmaceuticals-inc-sndx-position-held-by-schwab-charles-investment-management-inc.html.

Shares of Syndax Pharmaceuticals, Inc. (SNDX) opened at $8.37 on Wednesday. Syndax Pharmaceuticals, Inc. has a 12-month low of $6.31 and a 12-month high of $15.70.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, November 7th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.12. Syndax Pharmaceuticals had a negative return on equity of 57.90% and a negative net margin of 4,304.34%. The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.30 million. During the same quarter last year, the company earned ($0.84) EPS. The business’s quarterly revenue was up .0% on a year-over-year basis. equities analysts predict that Syndax Pharmaceuticals, Inc. will post -3.1 EPS for the current year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply